Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

12.22USD
9 Dec 2016
Change (% chg)

$0.29 (+2.43%)
Prev Close
$11.93
Open
$12.00
Day's High
$12.50
Day's Low
$11.94
Volume
70,902
Avg. Vol
95,806
52-wk High
$27.08
52-wk Low
$9.40

ESPR.OQ

Chart for ESPR.OQ

About

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies... (more)

Overall

Beta: 2.13
Market Cap(Mil.): $275.61
Shares Outstanding(Mil.): 22.55
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -2.62 -- --
ROI: -21.31 -0.36 15.24
ROE: -21.48 -0.94 16.58

BRIEF-Esperion Therapeutics reports qtrly loss per share $0.77

* Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million

Nov 03 2016

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

Oct 13 2016

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

Sep 27 2016

BRIEF-Esperion Therapeutics reports Q2 net loss of $14 mln

* Estimates current cash resources are sufficient to fund operations into 2019

Aug 04 2016

BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid

* Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016

Jun 28 2016

Earnings vs. Estimates